Daily Ards Research Analysis
Analyzed 4 papers and selected 3 impactful papers.
Summary
Three complementary ARDS-focused papers span mechanistic, evidence-synthesis, and practice-guidance domains. A meta-analysis quantifies delirium burden in ARDS and ties it to worse outcomes, a translational study links GMP EV manufacturing to human 3D lung inflammatory models revealing donor- and compartment-specific immunomodulation, and a consensus statement clarifies nebulizer selection for aerosol therapy during NIV and high-flow therapy.
Research Themes
- Delirium epidemiology and outcomes in ARDS
- Cell-free immunomodulation via MSC-derived EVs in human 3D lung models
- Optimizing aerosol drug delivery during NIV and high-flow therapy
Selected Articles
1. Unraveling the Link: A Systematic Review and Meta analysis of Acute Respiratory Distress Syndrome and Delirium.
Across 13 studies (N=10,052), delirium affected 41% of ARDS patients and was consistently linked to longer mechanical ventilation and ICU stays. The risk of delirium was higher versus controls but not statistically significant, underscoring heterogeneity and confounding while reinforcing prevention and mitigation strategies.
Impact: Provides the most up-to-date, registered synthesis quantifying delirium prevalence and outcome associations in ARDS, informing ICU care pathways.
Clinical Implications: Reinforces systematic delirium prevention in ARDS (sedation minimization, early mobilization, sleep/vision/hearing support) and prioritizes routine delirium screening with validated tools.
Key Findings
- Delirium prevalence among ARDS patients was 41% (95% CI 23%–58%).
- Compared with controls, delirium risk in ARDS was higher but not statistically significant (RR 1.34, 95% CI 0.63–2.83).
- Delirium was consistently associated with longer ICU length of stay and duration of mechanical ventilation.
- No significant associations between delirium and comorbid depression or anxiety were detected.
Methodological Strengths
- Pre-registered review (PROSPERO) with systematic multi-database search and random-effects meta-analysis
- Structured risk of bias assessment using RoB2 and ROBINS-I
Limitations
- Substantial heterogeneity across studies and variable delirium/ARDS definitions
- Predominantly observational evidence with residual confounding and limited RCT data
Future Directions: Harmonize delirium definitions and assessment timing in ARDS, conduct prospective cohorts and pragmatic RCTs targeting sedation strategies and early mobilization.
BACKGROUND: Acute Respiratory Distress Syndrome (ARDS) is a critical condition characterized by severe hypoxemia and pulmonary edema, often resulting from pneumonia, sepsis, trauma, or aspiration. It affects 10-15% of ICU patients and is associated with high mortality rates (30-40%). Delirium, an acute cognitive impairment, is prevalent in critically ill patients, particularly in the ICU, and correlates with adverse outcomes. OBJECTIVE: This systematic review and meta-analysis aim to summarize the current evidence regarding the relationship between ARDS and delirium, focusing on the prevalence of delirium in ARDS patients, its impact on delirium development and mortality, potential correlations between the two conditions, and their clinical outcomes. METHODS: A systematic search was conducted across PubMed, Scopus, and Web of Science from inception until September 2024, leading to the identification of 838 records. Pooled risk ratios and prevalence were calculated using a random-effects model. The risk of bias was assessed using the revised Cochrane risk of bias tool for randomized trials (RoB2) and Risk of Bias in non-randomized studies of interventions (ROBINS-I) tool. RESULTS: Thirteen studies involving 10,052 patients with ARDS were included. The pooled prevalence of delirium among ARDS patients was 41% (95% CI: 23%-58%), with substantial heterogeneity. Meta-analysis showed a higher risk of delirium among ARDS patients compared with controls; however, this association was not statistically significant (RR 1.34, 95% CI: 0.63-2.83). No statistically significant associations were observed between delirium and comorbid depression or anxiety. Delirium in ARDS patients was consistently associated with prolonged ICU stay, longer mechanical ventilation, and adverse clinical outcomes. CONCLUSION: Patients with ARDS frequently experience delirium, resulting in extended ICU admissions, prolonged mechanical ventilation, and cognitive impairment. Hypoxia, inflammation, sedation, and psychological factors contributes to delirium risk in ARDS patients. A multidisciplinary approach incorporating sedative minimization, early mobilization, and psychological support may mitigate delirium and improve patient outcomes. PROSPERO REGISTRATION NUMBER: (CRD42024564895): https://www.crd.york.ac.uk/PROSPERO/view/CRD42024564895.
2. Bioreactor-derived EVs from placental MSCs show context- and donor-specific immunomodulatory trends in human 3D lung inflammatory models.
GMP-compliant 3D bioreactor manufacturing increased EV yields while maintaining quality, and hPSC-EVs produced donor- and context-specific immunomodulation in human 3D airway models of CF and ARDS. EVs consistently induced IL-10 and Arginase-1 in macrophages and showed compartment-specific effects distinct from parental cells.
Impact: Introduces an end-to-end translational pipeline linking GMP EV manufacturing to advanced human 3D lung inflammatory models, revealing donor/context dependencies critical for cell-free therapeutics.
Clinical Implications: Supports EVs as distinct, cell-free immunomodulators for inflammatory lung diseases and underscores the need for donor screening, potency assays, and compartment-aware delivery strategies before clinical translation.
Key Findings
- 3D stirred-tank bioreactor culture significantly increased EV yield without compromising quality.
- Marked donor-dependent variability shaped distinct, model-specific immunomodulatory profiles of hPSC-EVs.
- EVs and parental hPSCs elicited divergent responses across immune and epithelial compartments.
- Macrophage IL-10 and Arginase-1 induction (up to 25-fold) was a consistent trend across conditions.
Methodological Strengths
- GMP-compliant scalable EV production using 3D microcarrier bioreactors and tangential flow filtration
- Advanced human 3D airway models (air-liquid interface with primary epithelium and macrophages) enabling compartment-specific readouts
Limitations
- In vitro human models without in vivo validation
- Limited donor numbers and substantial heterogeneity may constrain generalizability
Future Directions: Expand donor cohorts, develop potency and release assays, and evaluate EV efficacy and biodistribution in preclinical in vivo ARDS models.
BACKGROUND: Extracellular vesicles (EVs) derived from mesenchymal stromal cells (MSCs) have garnered attention as cell-free therapeutics due to their regenerative and immunomodulatory potential. Human placenta-derived stromal cells (hPSCs) are a particularly promising source owing to their accessibility, scalability, and superior proliferative capacity-yet the functional behavior of their EVs, especially in inflammatory disease contexts, remains poorly defined. This study introduces a novel integrated approach, combining a 3D microcarrier bioreactor for scalable EV production with advanced 3D human airway disease models, to resolve how donor variability and inflammatory context shape the immunomodulatory activity of hPSC-EVs. METHODS: hPSCs were expanded under Good Manufacturing Practice (GMP)-compliant conditions in both conventional 2D cultures and 3D stirred-tank bioreactors using microcarrier technology. EVs were isolated from conditioned media via tangential flow filtration and characterized by fluorescent nanoparticle tracking analysis (fNTA), flow cytometry and protein content. Functional effects of hPSCs and EVs were assessed in PBMC co-cultures and two human 3D airway models-cystic fibrosis (CF) and acute respiratory distress syndrome (ARDS)-based on the Epithelix SmallAir™ platform, integrating primary airway epithelium and macrophages at the air-liquid interface. Inflammation was induced with TNF-α (CF) or LPS (ARDS), and EVs or hPSCs were administered to both apical and basal compartments. RESULTS: 3D culture significantly increased EV yield without compromising quality. A key finding was a substantial donor-dependent variability in both hPSC and EV activity, which translated into distinct, model-specific immunomodulatory profiles. Notably, EV- and hPSC-mediated responses diverged across immune and epithelial compartments, indicating that EVs do not simply recapitulate parental cell function. In the 3D models, despite substantial heterogeneity, induction of IL-10 and Arginase-1 (up to 25-fold) in the macrophage compartment emerged as a consistent trend across experimental conditions. In contrast, parental hPSCs showed broader but less predictable cytokine modulation, including variable TNF-α suppression and context-specific effects across donors. CONCLUSIONS: Our findings demonstrate that hPSC- and EV-mediated immunomodulation is highly context-dependent and cannot be predicted solely from donor identity or culture format. Rather than identifying a single optimal condition, this study highlights the need for larger donor cohorts and functional profiling in advanced human models and supports the use of EVs as distinct, cell-free immunomodulatory entities with compartment-specific activity. Together, this work provides a translational framework linking GMP-compliant EV manufacturing with functionally relevant human disease modeling.
3. Aerosol therapy during noninvasive ventilation (NIV) and nasal high-flow therapy (HFT): current technology and consensus-based recommendations.
An expert consensus, informed by a systematic literature search, recommends vibrating mesh nebulizers for superior lung deposition during NIV and high-flow therapy, while recognizing scenarios where jet nebulizers are appropriate. Recommendations emphasize patient-specific, indication-aligned device selection balancing technical and economic factors.
Impact: Provides pragmatic, consensus-based guidance on aerosol delivery under NIV/HFT where standardized recommendations have been lacking, with clear device-specific implications.
Clinical Implications: Supports adopting VMNs as first-line nebulizers under NIV/HFT when feasible, standardizing workflows and potentially improving drug deposition in acute respiratory failure including ARDS.
Key Findings
- Vibrating mesh nebulizers achieved better lung deposition than jet nebulizers during NIV and HFT.
- Jet nebulizers remain appropriate when VMNs are unavailable, for highly viscous solutions, or under budget constraints.
- Recommendations were developed via an interdisciplinary, multi-stage consensus informed by a systematic PubMed search through November 2025 and evidence grading.
Methodological Strengths
- Systematic evidence gathering across clinical, technical, and guideline sources with explicit evidence grading
- Interdisciplinary panel (pulmonology and intensive care) and multi-stage consensus process
Limitations
- Recommendations rely on heterogeneous evidence with limited RCTs directly under NIV/HFT conditions
- Generalizability to ARDS-specific contexts may vary; device performance can depend on interface and ventilator settings
Future Directions: Prospective comparative trials under standardized NIV/HFT settings to quantify clinical endpoints and cost-effectiveness of VMN vs JN across drug classes.
BACKGROUND: Aerosol therapy is an essential procedure in the treatment of acute and chronic respiratory diseases. Currently, there are no up-to-date guidelines from German-speaking countries on the selection and use of nebulizer systems in patients undergoing high-flow therapy via nasal cannula (HFT) and non-invasive ventilation (NIV). METHODS: An interdisciplinary panel of experts consisting of pulmonologists and intensive care physicians developed practice-oriented recommendations for aerosol therapy under HFT and NIV. The evidence base was derived from a systematic search of the PubMed database of the US National Library of Medicine up to and including November 2025.Publications on clinical studies, reviews, guideline documents, and technical reports were included. The respective level of evidence of the information was evaluated. The recommendations were agreed upon in a multi-stage process. RESULTS: Aerosol administration under HFT and NIV with a vibrating mesh nebulizer (VMN) achieved better lung deposition compared to the use of a jet nebulizer (JN). A JN is suitable if VMNs are not available, if highly viscous drug solutions are to be nebulized, or if there are budgetary limitations. CONCLUSION: The choice and application of the nebulizer system should be patient-specific, consistent with the indication, taking into account technical, clinical, and economic requirements. Die Aerosoltherapie ist ein essenzielles Verfahren in der Behandlung akuter und chronischer Atemwegserkrankungen. Derzeit existiert keine aktuelle Leitlinie aus den deutschsprachigen Ländern zur Auswahl und Anwendung von Verneblersystemen bei Patienten unter High-Flow-Therapie via Nasenkanüle (HFT) und nichtinvasiver Beatmung (NIV).Ein interdisziplinäres Expertengremium aus Pneumologen und Intensivmedizinern entwickelte praxisorientierte Empfehlungen zur Aerosoltherapie unter HFT und NIV. Die Evidenzgrundlage bildete eine systematische Recherche in der Datenbank PubMed der US National Library of Medicine bis einschließlich November 2025.Einbezogen wurden Publikationen zu klinischen Studien, Übersichtsarbeiten, Leitliniendokumente und technische Berichte. Der jeweilige Evidenzgrad der Informationen wurde bewertet. Die Empfehlungen wurden in einem Mehrstufenverfahren konsentiert.Die Aerosolapplikation unter HFT und NIV mit einem Vibrating-Mesh-Vernebler (VMN) führt zu einer besseren Lungendeposition im Vergleich zur Verwendung eines Jet Nebulizers (JN). Ein JN ist geeignet, wenn VMN nicht verfügbar sind, hochvisköse Medikamentenlösungen vernebelt werden sollen oder wenn budgetäre Limitationen bestehen.Die Wahl und Anwendung des Verneblersystems sollte patientenindividuell, indikationsbezogen und unter Berücksichtigung technischer、臨床的および経済的要件に沿って行われるべきです。